Hot or Not, Stock Market Edition: 04/07/2026

Happy Tuesday. Here’s what’s making moves in our market-beating Zen Ratings system today:

• Hot: Semiconductor player Photronics (PLAB) looks poised to outperform; medical device maker Merit Medical Systems (MMSI) is gaining momentum
• Not: Nektar Therapeutics (NKTR) is losing steam after a 70%+ run; regional banking outfit Central Bancompany (CBC) is hitting a rough patch

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

🔥 HOT:  Despite disappointing price action to the tune of a 20% drop in the past 3 months, medical device maker Merit Medical Systems (MMSI) is getting fresh attention following its acquisition of View Point Medical for approximately $140 million. The company just announced it has completed the merger transaction, making View Point a wholly-owned subsidiary and expanding its healthcare technology portfolio. The Zen Ratings support the bullish case — the stock holds a Zen Rating of B (Buy), ranking in the top 6% of stocks we track overall (so close to an A rating it can practically taste it — that tier is reserved for the top 5%). Looking at its Component Grades, it scores particularly well with an A Grade for Safety and B Grades for AI, Sentiment, and Value. The bottom line? The View Point acquisition demonstrates Merit's aggressive growth strategy, and with exceptional safety metrics plus solid fundamentals across multiple factors, this appears to be a buy-the-dip opportunity for investors seeking exposure to the medical technology space.

🥶 NOT: Despite recent Phase 2b trial data and the fact that the stock is up 77% in the past few months, biotech player Nektar Therapeutics (NKTR) may be a lemon in disguise. Our Zen Ratings system rates it a D (Sell), putting it in the lower tiers of the 4600+ stocks we track based on fundamentals. Momentum is the only strong Component Grade it boasts; elsewhere, the scores are ho-hum (Cs for Growth, Sentiment, and Financials) or downright dismal (Ds for Value, Safety, and from our proprietary AI Factor). The bottom line? Even with proof-of-concept in hand, investors should be cautious — Nektar's rock-bottom ratings and brutal price action suggest better places to park your money while this biotech story plays out. (See 260 better-rated biotechs here.)

🔥 HOT: Semiconductor equipment maker Photronics (PLAB) is on fire, with 99% gains in the past year — but even better, fundamentals match the momentum and suggest there’s more room to run. PLAB boasts strong ROIC, exceptional cash flow, and a debt-free balance sheet — exactly the types of things that make institutional investors take notice. Right now, shares are riding momentum across the broader tech sector amid optimism for a swifter end to the Middle East conflict, with reports of conciliatory steps between the U.S. and Iran easing supply chain concerns. PLAB was recently upgraded to a Zen Rating of A (Strong Buy), and currently ranks in the top 3% of the 4600+ stocks we track based on a 115-factor review. Looking at the Component Grades, it earns solid scores all around: A Grade for Safety and Value and a B Grade for Financials, Momentum, and Sentiment. The verdict? Keep an eye on this one. Photronics is combining fortress-like fundamentals with positive sector tailwinds, making it a compelling play in the semiconductor equipment space. (See more stocks with insane upside potential here.)

🥶 NOT: Regional banks are getting squeezed as depositors chase higher yields elsewhere, driving up funding costs and quietly crushing profit margins. Regional banking outfit Central Bancompany (CBC) is a good case study/cautionary tale. The stock is feeling the margin pinch as rising deposit costs outpace loan yields, putting pressure on its core earnings engine — and it shows in the totally flat price action (it’s gained a mere 1% in the past 3 months). The stock currently earns a D (Sell) Rating from our Zen Ratings, with matching Ds in several Component Grade areas like Financials, Growth, and Value, painting a picture of fundamental weakness across multiple dimensions. The bottom line? With price target cuts, weak performance across key metrics, and a D-grade Zen Rating, Central Bancompany appears to be stuck in traffic with the rest of the names in the D-rated Banking industry. 

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.